Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 11.8% – What’s Next?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) was down 11.8% on Thursday . The stock traded as low as $20.53 and last traded at $20.3230. Approximately 2,180,485 shares changed hands during trading, a decline of 24% from the average daily volume of 2,871,157 shares. The stock had previously closed at $23.03.

More Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Wedbush said Sarepta’s commercial portfolio alone could support a higher valuation, suggesting the market may be underappreciating the company’s existing business. Sarepta Therapeutics’ Commercial Portfolio Alone Should Support Higher Valuation, Wedbush Says
• Positive Sentiment: Sarepta’s Q1 results beat estimates on both earnings and revenue, and management maintained its 2026 outlook, reinforcing that the company is still generating solid financial results despite pressure on Elevidys. Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates
• Neutral Sentiment: Analysts remained divided, with J.P. Morgan keeping a Hold rating and Citi reiterating a Sell rating, reflecting uncertainty around pipeline execution and regulatory risk. Safety Overhangs and Regulatory Uncertainty Reinforce Sell Rating and Unchanged $13 Price Target
• Negative Sentiment: Several reports highlighted that Elevidys demand has weakened after a regulatory crackdown, which is the main reason the stock is under pressure even after the earnings beat. SRPT stock plunges 7% after-hours as Elevidys demand slumps — CEO still sees return to growth

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on SRPT shares. Oppenheimer reissued an “outperform” rating and set a $37.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, March 19th. Jefferies Financial Group restated a “buy” rating and set a $30.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, March 3rd. Barclays assumed coverage on Sarepta Therapeutics in a research note on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 price target on the stock. Wells Fargo & Company dropped their price target on Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. Finally, Needham & Company LLC restated an “underperform” rating on shares of Sarepta Therapeutics in a research note on Thursday, March 26th. Nine research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have given a Sell rating to the company. Based on data from MarketBeat, Sarepta Therapeutics presently has an average rating of “Hold” and an average target price of $27.71.

Sarepta Therapeutics Stock Down 4.1%

The business has a 50 day moving average of $19.77 and a 200-day moving average of $20.30. The stock has a market cap of $2.11 billion, a PE ratio of -20.78, a P/E/G ratio of 0.32 and a beta of 0.26. The company has a current ratio of 4.63, a quick ratio of 1.48 and a debt-to-equity ratio of 0.56.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share for the quarter, beating the consensus estimate of $0.98 by $2.18. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The company had revenue of $730.80 million for the quarter, compared to the consensus estimate of $474.16 million. During the same period last year, the business posted ($3.42) EPS. The company’s revenue was down 1.9% on a year-over-year basis. Equities research analysts predict that Sarepta Therapeutics, Inc. will post 2.89 EPS for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $17.02, for a total value of $123,207.78. Following the transaction, the director directly owned 1,765 shares in the company, valued at approximately $30,040.30. This trade represents a 80.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. grew its stake in shares of Sarepta Therapeutics by 7.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 8,751 shares of the biotechnology company’s stock valued at $190,000 after purchasing an additional 636 shares during the last quarter. Sigma Planning Corp grew its stake in shares of Sarepta Therapeutics by 4.3% in the 1st quarter. Sigma Planning Corp now owns 61,060 shares of the biotechnology company’s stock valued at $1,329,000 after purchasing an additional 2,515 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of Sarepta Therapeutics by 2.5% in the 1st quarter. Principal Financial Group Inc. now owns 509,552 shares of the biotechnology company’s stock valued at $11,088,000 after purchasing an additional 12,277 shares during the last quarter. Fifth Third Bancorp boosted its stake in shares of Sarepta Therapeutics by 2,138.9% in the first quarter. Fifth Third Bancorp now owns 25,949 shares of the biotechnology company’s stock valued at $565,000 after buying an additional 24,790 shares in the last quarter. Finally, Hsbc Holdings PLC boosted its stake in shares of Sarepta Therapeutics by 65.6% in the first quarter. Hsbc Holdings PLC now owns 55,549 shares of the biotechnology company’s stock valued at $1,220,000 after buying an additional 22,001 shares in the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.